| Campaign Committee |
Timothy Wollaeger has more than 30 years’ experience in the medical products and biotechnology fields, in both corporate management and venture capital. Mr. Wollaeger joined Sanderling Ventures as a managing firector in 2002, and opened the firm’s San Diego office. Mr. Wollaeger serves on the board of directors for several Sanderling portfolio companies, including Alteer, Asteres, and Triage Wireless. He is chairman of the board of directors for Chimerix and Digirad (NASDAQ: DRAD) and he is chairman and CEO of Harkness Pharmaceuticals.
Prior to joining Sanderling in 1994, Mr. Wollaeger founded the venture capital firm Kingsbury Capital Partners. At Kingsbury, seed and early-stage investing was combined with active management, and portfolio companies included Aurora Biosciences, Amylin Pharmaceuticals (NASDAQ: AMLN), Senomyx (NASDAQ: SNMX), and Althea Technologies. He was named E&Y San Diego’s Entrepreneur of the Year in 1995 and Corporate Director of the Year in 2001.
Prior to Kingsbury Capital Partners, Mr. Wollaeger helped found Columbia Hospital Corporation in 1990, and was its senior vice president and member of its board of directors until 1994. In 1986, Mr. Wollaeger became a founding general partner of Biovest, a San Diego–based venture capital firm. At Biovest, he helped found and remained an active board member in Pyxis, Vical (NASDAQ: VICL), and Biosite (NASDAQ: BSTE). All three of these companies became public, and Pyxis was acquired by Cardinal Health in 1996 for $1 billion.
In 1983, Mr. Wollaeger joined Hybritech, Inc., San Diego’s first biotechnology company, as vice president and chief financial officer until Hybritech was acquired by Eli Lilly & Co. (NYSE: LLY) in 1986. He began his career in the life science at Baxter International, where he was a manager of Operations Analysis. His last position was vice president and general manager of the company’s operations in Mexico.
Mr. Wollaeger earned a BA in Economics from Yale in 1966, served as an officer in the U.S. Navy for three years, and earned an MBA from the Stanford Graduate School of Business in 1971.